Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo
about
Adeno-associated Virus as a Mammalian DNA VectorAnimal models of hemophiliaProgress and prospects: immune responses to viral vectorsAAV's anatomy: roadmap for optimizing vectors for translational successTransduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle.A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer.The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaquesInfluence of immune responses in gene/stem cell therapies for muscular dystrophies.Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brainAAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypesSingle amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8+ T CellsAdeno-associated virus capsid antigen presentation is dependent on endosomal escape.Evading the immune response upon in vivo gene therapy with viral vectors.Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression.Immune responses to AAV vectors: overcoming barriers to successful gene therapySilencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy.Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.A small regulatory element from chromosome 19 enhances liver-specific gene expression.Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.Cellular immune response to cryptic epitopes during therapeutic gene transfer.Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy.The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.Transient transfection methods for clinical adeno-associated viral vector production.Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model.Targeted gene therapy for the treatment of heart failure.Manipulating Immune Tolerance with Micro-RNA Regulated Gene Therapy.Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors.The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.Continuous CD8⁺ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery.Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
P2860
Q26782605-13E1A14B-78F4-4776-86CD-21FEA85298A1Q27012571-0816061C-7249-4953-B62E-E9F11CA94711Q28264531-AEEA1CF2-B8F8-48C8-BE64-D1445E8CB93EQ33659389-EC5A557D-2E66-4E46-8D2A-8ED311856124Q33713019-99BB5D19-04D8-4F72-A316-C421114F8AF8Q33713730-E407AA58-7D73-4B73-88BE-ADE75551B91AQ33730459-E731A24F-24D7-414A-96E7-3AD0BB5D4812Q33736192-E82A2D28-B44C-4E14-8CA7-9F8F27319F15Q33792012-F5BE5667-BDC0-4233-991A-67DAFF5D9400Q33938435-FFFA9089-35D5-4427-A46D-3CA9B1D043E7Q34370111-693F89A9-3348-4120-8BCF-46B349F91F21Q34621723-65F1433A-81FE-4429-8C3D-890243062DD9Q34718452-EF607414-9479-4DF2-92E7-7CF67B3E2A3CQ36106408-4C5DA88D-7CD1-43B9-9989-DE8A289B5887Q36171820-E8BC5F42-34BD-4D44-83E4-77306AD10A98Q36365372-1ECE7BDF-3012-403F-A2E6-74F92FAC081FQ36638203-5283798D-D87C-44D7-B429-D401A3DB640CQ36644230-31247126-3ACF-4FA1-AD9E-63C4DCC41C33Q36709834-93AE4468-9287-482D-831D-4598E3FAF5DCQ36848699-9F351506-79DC-47E6-9E15-A646F61A5604Q36976498-7A4E72B7-CC87-4339-9FF0-DF0A2BBCD33CQ36983740-742AA82D-3B49-415C-94FB-DF1B327C3070Q37066228-4AB22811-F650-4407-AC57-821254A1B491Q37127246-3D3254C7-0339-472A-9DD3-786FFB150CD8Q37148191-D46FAF09-C5B0-4782-B0E8-3D677CAE1AD2Q37209197-7480D08D-5ECF-48E4-98AD-E6BEAD9647FBQ37250034-1148FA1D-C15C-4953-B181-C4EE85DA64CEQ37277411-139C16B7-C6D4-416E-A61F-7FC722D8E494Q37286686-2BC29B06-5CCE-412B-8A36-9F4983017771Q37479802-2C69641C-9DB7-4E24-A930-3E08778FD08FQ37686976-8FB90278-15C5-420D-9DA8-61A6CAA44EBEQ37878086-320B3D94-561D-4FEA-853F-D63C860FCC3DQ37965158-39B4B109-B451-4A93-8875-4053B5E23015Q38191212-582CE2AB-B42F-484C-9633-7F14F5A6211DQ38539938-EC5C055A-3223-453A-B769-E49C675D4BFBQ38959186-DA7ABAB4-8C7B-4C24-BDF4-F518F98FD70CQ39501488-84BF9180-9E9E-4DC9-8008-1C50DC6DC70CQ39519818-29833BB6-79DC-481D-8FE1-6486A86E8A42Q39553052-FA41A6CA-64D3-4970-AB98-393863AEB160Q39860625-3CA1C7AF-F5B3-48E7-A5F1-97257559F8CE
P2860
Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Adeno-associated virus type 2 ...... essing the AAV2 capsid in vivo
@ast
Adeno-associated virus type 2 ...... essing the AAV2 capsid in vivo
@en
type
label
Adeno-associated virus type 2 ...... essing the AAV2 capsid in vivo
@ast
Adeno-associated virus type 2 ...... essing the AAV2 capsid in vivo
@en
prefLabel
Adeno-associated virus type 2 ...... essing the AAV2 capsid in vivo
@ast
Adeno-associated virus type 2 ...... essing the AAV2 capsid in vivo
@en
P2093
P2860
P356
P1433
P1476
Adeno-associated virus type 2 ...... essing the AAV2 capsid in vivo
@en
P2093
Aravind Asokan
Brian Zeithaml
Chengwen Li
Matthew Hirsch
R Jude Samulski
P2860
P304
P356
10.1128/JVI.00529-07
P407
P577
2007-05-02T00:00:00Z